John Fesko Sells 1,438 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 1,438 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total value of $291,683.92. Following the completion of the transaction, the insider owned 185,782 shares in the company, valued at approximately $37,684,020.88. This trade represents a 0.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $59,992.56.
• On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $344,520.80.
• On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $144,319.91.

Natera Price Performance

NASDAQ NTRA opened at $223.37 on Friday. The company has a market cap of $31.99 billion, a PE ratio of -137.04 and a beta of 1.57. The stock’s 50 day simple moving average is $202.37 and its 200-day simple moving average is $215.69. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter last year, the business posted ($0.41) earnings per share. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. BTIG Research decreased their target price on Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. William Blair began coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, Morgan Stanley cut their price target on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.60.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC increased its holdings in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC increased its stake in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its stake in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in Natera during the second quarter worth $298,000. Finally, WINTON GROUP Ltd acquired a new stake in Natera during the second quarter worth $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.